ikema:
sarclisa + CARFILZOMIB
AND DEXAMETHASONE (Kd)
ikema Patient Profiles
Treating with sarclisa + Kd as early as
first relapse1
Current patient information
68 years of age
High: t(4;14)
Presence of gain(1q21)
Diagnosis
Diagnosed 19 months ago after persistent worsening bone pain prompted MRI that identified humeral lesion
1st line
VRd induction → ASCT → bortezomib and lenalidomide maintenance (VGPR for 13 months posttransplant)
1st relapse
Rapid increase in M-spike and abrupt onset of bone pain with PET scan showing FDG-avid disease in the axial and appendicular skeleton
2nd-line treatment considerations for Alice
- Rapid, aggressive disease progression
- High cytogenetic risk
- Presence of gain(1q21)
- Double refractory to lenalidomide and bortezomib
- Candidate for a triplet combination that includes a multimodal anti-CD38 mAb and a novel PI
This is a hypothetical case study portrayed by an actor and should not substitute a healthcare provider's decision.
consider sarclisa + Kd AS EARLY AS FIRST RELAPSE1
ASCT=autologous stem cell transplant; ECOG PS=Eastern Cooperative Oncology Group performance status; FDG=fluorodeoxyglucose; mAb=monoclonal antibody; MRI=magnetic resonance imaging; PET=positron emission tomography; PI=proteasome inhibitor; RRMM=relapsed or refractory multiple myeloma; VGPR=very good partial response; VRd=bortezomib, lenalidomide, dexamethasone.
Review the broad and diverse patient population studied in the phase 3 IKEMA trial1
Get in touch with your local sarclisa representative
IKEMA Trial Summary Brochure
An informative brochure that includes the IKEMA trial results for SARCLISA + Kd vs Kd alone
Current patient information
55 years of age
Standard
44 mL/min/1.73 m2
Diagnosis
Diagnosed ~3 years ago after acute onset of renal insufficiency and hypercalcemia
1st line
VRd induction → ASCT → lenalidomide maintenance (CR for 27 months posttransplant;
recovery of renal function)
1st relapse
Relapsed with hypercalcemia, anemia, and recurring renal insufficiency
2nd-line treatment considerations for Charles
- High symptom burden at early relapse on lenalidomide maintenance
- Impaired renal function
- Refractory to lenalidomide
- Candidate for a triplet regimen that includes a multimodal anti-CD38 mAb and a novel PI
This is a hypothetical case study portrayed by an actor and should not substitute a healthcare provider's decision.
consider sarclisa + Kd AS EARLY AS FIRST RELAPSE1
ASCT=autologous stem cell transplant; CR=complete response; ECOG PS=Eastern Cooperative Oncology Group performance status; eGFR=estimated glomerular filtration rate; mAb=monoclonal antibody; PI=proteasome inhibitor; RRMM=relapsed or refractory multiple myeloma; VRd=bortezomib, lenalidomide, dexamethasone.
Review the broad and diverse patient population studied in the phase 3 IKEMA trial1
Get in touch with your local sarclisa representative
IKEMA Trial Summary Brochure
An informative brochure that includes the IKEMA trial results for SARCLISA + Kd vs Kd alone